The role of maintenance endocrine treatment after docetaxel combined with trastuzumab+pertuzumab in HER+/HR+ metastatic breast cancer

The role of maintenance endocrine treatment after docetaxel combined with trastuzumab+pertuzumab in HER+/HR+ metastatic breast cancer

Piotr J. Wysocki Piotr J. Wysocki

Piotr J. Wysocki

MD, PhD, medical oncologist; Professor of Medicine, Head of Department of Oncology, Jagiellonian University Hospital. ASCO International Affairs Committee member

发布日期: 2023年3月20日
+ 关注

Pretty robust data confirms that HER2+/HR+ metastatic breast cancer patients should receive endocrine treatment combined with pertuzumab+trastuzumab after stopping docetaxel. The addition of ET was associated with significantly improved 5-year PFS (HR 0.58, CI 0.37–0.89, p = 0.014) and OS (HR 0.52, CI 0.31–0.90, p = 0.018), with no increase in adverse events. https://link.springer.com/article/10.1007/s10549-022-06856-1

要查看或添加评论，请登录

Piotr J. Wysocki的更多文章

社区洞察

其他会员也浏览了